Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors
Open Access
- 9 April 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 6, 106
- https://doi.org/10.3389/fvets.2019.00106
Abstract
Mast cell tumor (MCT) is the most common cutaneous neoplasm in dogs and wide surgical resection is the current first-line treatment. However, recurrence is common and often requires more specialist and expensive therapies. Tigilanol tiglate is a novel small molecule drug delivered by intratumoral injection that is currently under development to provide a new option for treating MCT. The aim of this study was to characterize a safe and effective dose of tigilanol tiglate for canine MCT and to gather preliminary data on the drug's pharmacokinetics. A multicenter, open-label, uncontrolled, non-randomized, dose de-escalation design was used. Eligibility was MCT stage I/IIa and a tumor size of 0.1–6.0 cm3. Dosing was based on tumor size (50% v/v tumor) and 3 drug concentrations (1.0, 0.5, 0.2 mg/mL) were evaluated. Twenty-seven dogs were treated in 3 dose de-escalation cohorts (10, 10, and 7 dogs, respectively). Efficacy at 21 days was defined using international accepted solid tumor response criteria (RECIST). Greatest efficacy (90% complete response) was observed at the highest drug concentration (1.0 mg/mL) and adverse events were generally low grade, mild and transient, and directly associated with the mode of action of the drug. Hematological and serum biochemistry were generally unremarkable with plasma concentration curves typical of a non-intravenous parenteral medication. Intratumoral treatment of MCT with tigilanol tiglate at a concentration of 1.0 mg/mL was highly efficacious and well-tolerated. These results support the drug's further development for the treatment of MCT and other solid tumors.Keywords
This publication has 15 references indexed in Scilit:
- Diagnostic accuracy of pre‐treatment biopsy for grading cutaneous mast cell tumours in dogsVeterinary and Comparative Oncology, 2017
- Prevalence and risk factors for mast cell tumours in dogs in EnglandCanine Genetics and Epidemiology, 2015
- Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse ModelsPLOS ONE, 2014
- Estimation of rat mammary tumor volume using caliper and ultrasonography measurementsLab Animal, 2013
- Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasmsJournal of the American Veterinary Medical Association, 2011
- PKC and the control of localized signal dynamicsNature Reviews Molecular Cell Biology, 2010
- Protein kinase C isozymes and the regulation of diverse cell responsesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2000
- Intratumoral Therapy of Cisplatin/Epinephrine Injectable Gel for Palliation in Patients With Obstructive Esophageal CancerAmerican Journal of Clinical Oncology, 2000
- Skin neoplasms of dogs in SydneyAustralian Veterinary Journal, 1987
- Neoplasms of the skin and subcutaneous tissues in dogs and catsBritish Veterinary Journal, 1986